Research analysts at Ameriprise Financial began coverage on shares of Tenet Healthcare (NYSE: THC) in a report released on Friday. The firm set a “buy” rating on the stock.
Shares of Tenet Healthcare (NYSE: THC) traded down 0.49% during mid-day trading on Friday, hitting $44.74. Tenet Healthcare has a one year low of $17.24 and a one year high of $45.00. The stock’s 50-day moving average is currently $39.91. The company has a market cap of $4.666 billion and a P/E ratio of 34.69.
Tenet Healthcare (NYSE: THC) last issued its quarterly earnings data on Tuesday, February 26th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.68 by $0.23. The company had revenue of $2.33 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. Analysts expect that Tenet Healthcare will post $2.76 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Tenet Healthcare from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday. They now have a $46.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Tenet Healthcare from $41.00 to $46.00 in a research note to investors on Tuesday. They now have a “neutral” rating on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Tenet Healthcare in a research note to investors on Friday, March 8th. They now have a $46.00 price target on the stock.
Tenet Healthcare Corporation, and its subsidiaries (Tenet) is an investor-owned health care services company whose subsidiaries and affiliates own and operate acute care hospitals, ambulatory surgery centers, diagnostic imaging centers and related health care facilities.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
